- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–703
of 703
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Seltorexant
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- ibrutinib, Placebo, Prednisone
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 38
- States / cities
- Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 29 more
- Conditions
- Psoriasis
- Interventions
- Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 29 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Placebo, Golimumab 100 mg, Golimumab 200 mg, Golimumab 400 mg, Golimumab 50 mg
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,065 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Roseville, California + 55 more
- Conditions
- Colitis, Ulcerative
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- TAR-210, Gemcitabine, MMC
- Combination Product · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 641 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 31 more